TABLE 1.
Patient characteristics (n = 43)
| No. (%) | |
|---|---|
| Age, median (range), y | 70 (41–83) |
| Gender | |
| Female | 27 (62.8) |
| Male | 16 (37.2) |
| Smoking history | |
| Never smoker | 18 (41.9) |
| Light or former smoker | 25 (58.1) |
| Histology | |
| Adenocarcinoma | 42 (97.7) |
| Non–small cell carcinoma not otherwise specified | 1 (2.3) |
| Clinical stage | |
| IIIB | 1 (2.3) |
| IV | 24 (55.8) |
| Postoperative recurrent disease | 18 (41.9) |
| ECOG performance status | |
| 0–1 | 33 (76.8) |
| 2 | 8 (18.6) |
| 3 | 2 (4.6) |
| CNS metastasis | |
| Present | 21 (48.9) |
| Absent | 22 (51.1) |
| EGFR mutation at the diagnosis | |
| Exon 19 deletion | 23 (53.5) |
| Exon 21 L858R | 18 (41.9) |
| Uncommon mutation | 2 (4.6) |
| T790M at pre‐treatment of dacomitinib | |
| T790M positive | 2 (4.6) |
| T790M negative | 31 (72.2) |
| Unknown | 10 (23.2) |
| Treatment history of osimertinib | 24 (55.8) |
| Treatment history of platinum chemotherapy | 34 (79.1) |
| Treatment history of anti VEGF antibody | 22 (51.2) |
| Previous EGFR‐TKI as first line | |
| Gefitinib | 16 (37.2) |
| Erlotinib | 5 (11.8) |
| Afatinib | 10 (23.2) |
| Erlotinib + bevacizumab | 2 (4.6) |
| Osimertinib | 9 (20.9) |
| Other clinical trial drug | 1 (2.3) |
| Treatment line of dacomitinib | |
| 2 | 6 (13.9) |
| 3 | 4 (9.3) |
| 4 | 12 (27.9) |
| 5 or later | 21 (48.9) |
| BMI | |
| <19 | 11 (25.6) |
| ≥19 | 32 (74.4) |
Abbreviations: BMI, body mass index; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PS, performance status; VEGF, vascular endothelial growth factor.